<DOC>
	<DOC>NCT02848651</DOC>
	<brief_summary>This is a Phase II, open-label, prospective, multicenter study designed to evaluate the efficacy and safety of single-agent atezolizumab in participants with treatment-naive locally advanced or metastatic NSCLC. In addition, the primary biomarker objective is to evaluate various predictive cutoffs for novel blood-based diagnostic assays.</brief_summary>
	<brief_title>A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST]</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Histologically or cytologically confirmed Stage IIIBIVB NSCLC Measurable disease per RECIST v1.1 Adequate hematologic and endorgan function Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods among women of childbearing potential Prior treatment with immunotherapy or chemotherapy for any stage NSCLC, including earlystage (neoadjuvant or adjuvant) disease Participants with epidermal growth factor receptor (EGFR) sensitizing mutations and anaplastic lymphoma kinase (ALK) rearrangements Active central nervous system (CNS) metastases requiring treatment Spinal cord compression not definitively treated or not clinically stable Leptomeningeal disease Uncontrolled tumorrelated pain Uncontrolled pleural or pericardial effusions or ascites requiring recurrent drainage Uncontrolled or symptomatic hypercalcemia Malignancies other than NSCLC within 5 years prior to randomization, except for those curatively treated with negligible risk of metastasis or death Pregnant or lactating women History of autoimmune disease, significant pulmonary disease, or significant cardiovascular disease Positive human immunodeficiency virus (HIV) or hepatitis B or C Active tuberculosis Severe infection or major surgery within 4 weeks, or antibiotic treatment for acute infection within 2 weeks prior to randomization Prior treatment with or hypersensitivity to study drug or related compounds Prior allogeneic bone marrow or solid organ transplant Receipt of a live attenuated vaccine within 4 weeks prior to randomization Treatment with systemic immunomodulators within 4 weeks or five halflives (whichever is shorter) prior to randomization Treatment with systemic corticosteroids within 2 weeks prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>